Court Grants Vizgen Motion to Expand Antitrust Case vs.10x, Harvard

A U.S. District Court judge has granted Vizgen’s motion to expand its antitrust case against rival 10x Genomics and Harvard University, citing new evidence that has surfaced during the case’s discovery phase.

Visiting Judge Matthew F. Kennelly of U.S. District Court for the District of Delaware is allowing Vizgen to amend its response to the lawsuit brought by 10x and Harvard by adding additional allegations that accuse 10x and Harvard of conspiring to monopolize the market by obstructing Vizgen’s ability to compete globally.

Vizgen cited as examples of anticompetitive activities what it called the unlawful bundling of 10x Genomics’ existing Chromium Single Cell Immune Profiling platform, and its Visium Spatial Gene Expression platform franchises with its Xenium In Situ single-cell spatial imaging platform, as well as what Vizgen alleged to be predatory pricing.

Kennelly also sided with Vizgen in granting the company additional time to depose witnesses, after concluding that some of Harvard’s witnesses “knowingly” engaged in deposition misconduct and purposeful delay. He also extended the case schedule, setting a new trial date in early February 2025.